Kodiak Sciences
Market cap $6.33B 65.4M shares (10-Q, Nov 9, 2026) × $96.80 close Nov 17, 2026
Most recent annual filing: 2026-03-31
- KSI-101 Ph3 toplineDec 2026KSI-101 Ph3 topline, Dec 2026, thesis-defining
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (8 active programs)
tabirafusp alfa tedromer
tabirafusp-ted · KSI-501KSI-101
KSI-102
- Undisclosed indication
KSI-103
- Undisclosed indication
Technology platforms
ABC Platform
Antibody Biopolymer Conjugate (ABC) platform — a proprietary drug delivery technology pairing free protein for immediate disease control with antibody conjugated to a high-molecular-weight biopolymer for extended ocular half-life and durability; used to develop retinal medicine candidates including Zenkuda and tabirafusp-ted
Targets: VEGF, IL-6
ABCD Platform
Antibody Biopolymer Conjugate Drug platform extending ABC to embed small molecule APIs into the biopolymer backbone for high drug-antibody ratio medicines; advancing duet programs for glaucoma (NLRP3 inhibitor + IOP-lowering molecule) and geographic atrophy (complement inhibitor + NLRP3 inhibitor); focus on ophthalmic and systemic multifactorial diseases.
Targets: NLRP3
VETi
Visual Engagement Technology and Imager — AI- and machine-learning-enabled wearable headset digital health platform with applications in retina care, identity security and cognitive sciences.
ABC
Antibody Biopolymer Conjugate platform — merges protein-based and chemistry-based therapies via molecular engineering; enables extended ocular half-life and durability for retinal vascular disease therapies including wet AMD, DR, RVO, DME, and MESI
Targets: VEGF, IL-6
ABCD
Antibody Biopolymer Conjugate Drug platform — extension of ABC platform enabling high drug-antibody ratio conjugation of small molecule APIs into the biopolymer backbone for sustained, multi-specific modulation; focus on ophthalmic diseases including glaucoma and geographic atrophy
Targets: NLRP3, complement pathway
Capital (as filed)
- Cash
- $88.7M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Operating cash flow
- −$43.9M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $88.7M cash per the update of Nov 12, 2026 — the company's own words as read there, not the filed figure
Offering documents (1)
- 2026-10-20 S-3ASR · Shelf registration
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (8)
- 2026-11-13 UPDATE: Kodiak Sciences (KOD) - The Faucet Is Running 🔒 Paid
- 2026-10-20 UPDATE: Kodiak Sciences (KOD) - The Raise Arrives as a Faucet 🔒 Paid
- 2026-09-30 UPDATE: Kodiak Sciences (KOD) - Baker Bros. Bought the Breakout ★ Distilled Pro
- 2026-09-29 UPDATE: Kodiak Sciences (KOD) - DAYBREAK Delivers the Six-Month Number 🔒 Paid
- 2026-08-14 UPDATE: Kodiak Sciences (KOD) - They Started a Third Phase 3 With $125.9M in the Bank 🔒 Paid
- 2026-05-08 UPDATE: Kodiak Sciences (KOD) - The Going Concern Footnote Nobody is Reading 🔒 Paid
- 2026-03-29 UPDATE: Kodiak Sciences (KOD) - The Franken-Formulation Gets Vindicated (and a New Name) 🔒 Paid
- 2026-01-29 Kodiak Sciences (KOD): Scientific Deep Dive for Lead and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (8 calls)
Every verdict Biotech Distilled has published on Kodiak Sciences, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-01-29 Watch Kodiak Sciences (KOD): Scientific Deep Dive for Lead and Pipeline Products Dilution risk is off the table for ~18 months and Baker Bros. insider buying is the tie-breaker, but the binary clinical risk warrants only a watch-list stance sized for a speculative position.
- 2026-03-29 Hold UPDATE: Kodiak Sciences (KOD) - The Franken-Formulation Gets Vindicated (and a New Name) GLOW2 validated the commercial formulation with clean safety, but after the stock doubled the risk-management call is to take principal off the table and let the rest ride into the Q3 DAYBREAK readout.
- 2026-05-08 Hold UPDATE: Kodiak Sciences (KOD) - The Going Concern Footnote Nobody is Reading Going-concern disclosure signals an imminent dilutive raise before the September DAYBREAK readout; the science is intact but the balance sheet is the new bear case, so hold house money and size any remaining position as a binary bet.
- 2026-08-14 Hold UPDATE: Kodiak Sciences (KOD) - They Started a Third Phase 3 With $125.9M in the Bank Cash fell to $125.9M with going-concern language intact and burn accelerating; a capital raise is imminent before or after DAYBREAK, so hold house money and size any remaining position as a binary bet on September.
- 2026-09-29 Hold UPDATE: Kodiak Sciences (KOD) - DAYBREAK Delivers the Six-Month Number Both DAYBREAK arms met non-inferiority and Zenkuda's safety is clean, but after a ~125% move the easy money is made; hold house money through the likely offering and into PEAK while KSI-501's IL-6 thesis remains unproven.
- 2026-09-30 Hold UPDATE: Kodiak Sciences (KOD) - Baker Bros. Bought the Breakout Baker Bros. buying at post-data prices (~$90) strengthens the insider signal and supports patience through the upcoming offering and into PEAK, but does not change the hold-house-money posture.
- 2026-10-20 Hold UPDATE: Kodiak Sciences (KOD) - The Raise Arrives as a Faucet The $350M ATM program at ~$91 removes the dilution-overhang risk on favorable terms (~6% illustrative dilution); hold house money into PEAK while gradually accumulating suits the ATM tape better than waiting for a single discounted block.
- 2026-11-13 Hold UPDATE: Kodiak Sciences (KOD) - The Faucet Is Running First ATM draw of $68.9M at ~$100/share improves the treasury with minimal dilution, but ALTO's primary endpoint was lowered to non-inferiority and the AI-guided dosing label risk is new; hold house money into PEAK as the cleanest remaining IL-6 test.
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (10 quotes from 6 filings)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“Enrollment of the first 300-patient cohort in the PEAK trial supporting Pivotal Analysis 1 has completed and topline results remain on track for a December 2026 release.”
matched to KSI-101 · topline data
-
-
-
“Phase 3 PEAK Study (KSI-101) – Pivotal Analysis 1 Topline Data Expected December 2026”
matched to KSI-101 · topline data
-
-
-
“Our third late-stage asset, KSI-101, is being developed for macular edema secondary to inflammation, or MESI, with our first topline readout from its Phase 3 program expected in December 2026.”
matched to KSI-101 · topline data
-
-
-
“Enrollment of the first 300-patient cohort in the PEAK trial supporting Pivotal Analysis 1 has completed and topline results are expected in December 2026.”
matched to KSI-101 · topline data -
“DAYBREAK has completed enrollment and topline data for the one-year primary endpoint are expected in September 2026.”
matched to Tarcocimab/KSI-501 · topline data · since happened Sep 28, 2026
-
-
-
“Topline data from Pivotal Analysis 1 are expected in December 2026.”
matched to KSI-101 · topline data -
“"We remain on track for September 2026 DAYBREAK Phase 3 topline results evaluating both Zenkuda and KSI-501 in treatment-naïve wet AMD, followed by December 2026 PEAK Phase 3 Pivotal Analysis 1 topline results evaluating KSI-101 in Macular Edema Secondary to Inflammation.”
matched to Tarcocimab/KSI-501 · topline data
-
-
-
“Enrollment of the first 300-patient cohort in the PEAK trial supporting Pivotal Analysis 1 has completed and topline results are expected in December 2026.”
matched to KSI-101 · topline data -
“Topline data from Pivotal Analysis 1 are expected in December 2026.”
matched to KSI-101 · topline data -
“DAYBREAK has completed enrollment and topline data for the one-year primary endpoint are expected in September 2026.”
matched to Tarcocimab/KSI-501 · topline data · since happened Sep 28, 2026
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (25)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 7, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 12, 2026ReleaseKodiak Sciences Announces Recent Business Highlights and Third Quarter 2026 Financial Results→ BD updateSummary on the 8-K
- Nov 12, 20268-KCurrent report: results of operations · EX-99.1→ BD updateKodiak's Q3 10-Q — filed after today's close — confirms cash has fallen to $88.7M with going-concern language still in place, but the ATM faucet has already delivered $68.9M in net proceeds post-quarter, leaving $280.4M still available. With the Zenkuda BLA due by year-end and PEAK topline data weeks away, the treasury picture has finally started improving — but the December binary is here.
- Nov 12, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Nov 11, 2026ReleaseKodiak Sciences to Present at Three Upcoming Investor Conferences
- Oct 20, 2026S-3ASRAutomatic shelf registration→ BD updateKodiak filed a $350M ATM shelf after today's close — the raise I've been flagging since May is no longer a prediction, it's a distribution agreement with J.P. Morgan already signed. The mechanism matters: dilution will drip through the tape, not land in a single priced block.
- Oct 7, 2026ReleaseKodiak Sciences to Present Clinical Data Across All Three Late-Stage Programs at AAO 2026BD extracted 3 program updates from this document → KOD pipeline
- Sep 30, 2026SCHEDULE 13D/A13D amendment→ BD updateTwo days after DAYBREAK vindicated the Franken-formulation, Baker Bros. filed a 13D/A disclosing they bought more shares — lifting their stake to 35.0% — the clearest vote of confidence yet from the fund that anchored Kodiak's turnaround.
- Sep 28, 2026ReleaseZenkuda and tabirafusp-ted Meet Primary Endpoints in Pivotal DAYBREAK Trial in wAMD, with Zenkuda Demonstrating a Potential New Standard-of-Care Profile with Strong Immediacy and Sustained Clinical Ef→ BD updateSummary on the 8-K
- Sep 28, 20268-KCurrent report: other events · EX-99.1→ BD updateDAYBREAK delivered a clean sweep: Zenkuda and tabirafusp-ted both hit primary endpoints in wet AMD, with 54% of Zenkuda patients on 6-month dosing and a near-zero inflammation signal — the Franken-formulation has now won three Phase 3s in a row, and a BLA is coming in Q4.BD extracted 2 program updates from this document → KOD pipeline
- Sep 25, 2026ReleaseKodiak Sciences to Present Topline Results on September 28, 2026 from DAYBREAK Pivotal Phase 3 Study of Zenkuda and KSI-501 in Patients with Wet Age-Related Macular DegenerationBD extracted 2 program updates from this document → KOD pipeline
- Aug 13, 2026ReleaseKodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial ResultsBD extracted 1 program update from this document → KOD pipeline
- Aug 13, 20268-KCurrent report: results of operations · EX-99.1
- Aug 13, 202610-QQuarterly report
- Aug 10, 2026ReleaseKodiak Sciences Announces First Patients Enrolled in Global Phase 3 ALTO trial of KSI-501 in Patients with Diabetic Macular Edema
- Aug 6, 2026ReleaseKodiak Sciences Completes Enrollment in First Pivotal Cohort in the Phase 3 PEAK Trial of KSI-101 for Macular Edema Secondary to Inflammation and Reaffirms Topline Clinical Data Release Remains on Tra
- Jun 4, 20268-KCurrent report: shareholder vote
- May 28, 2026ReleaseKodiak Sciences to Present at 2026 Jefferies Global Healthcare Conference
- May 7, 2026ReleaseKodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results
- May 7, 20268-KCurrent report: results of operations · EX-99.1
- May 7, 202610-QQuarterly report
- Apr 22, 2026DEFA14AProxy soliciting material
- Apr 22, 2026DEF 14AProxy statement
- Mar 31, 20268-KCurrent report: results of operations · EX-99.1
- Mar 31, 202610-KAnnual report
- Mar 27, 20268-KCurrent report: other events · EX-99.1
8 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 16, 2026SCHEDULE 13G/A13G amendment
- Nov 16, 2026SCHEDULE 13G/A13G amendment
- Aug 14, 2026SCHEDULE 13GPassive >5% holder (13G)
- May 15, 2026SCHEDULE 13GPassive >5% holder (13G)
- Apr 27, 2026SCHEDULE 13GPassive >5% holder (13G)
- Apr 23, 2026ARSAnnual report to shareholders
- Apr 2, 2026SCHEDULE 13GPassive >5% holder (13G)
- Mar 31, 2026S-8Employee plan registration